Skip to main content

Advertisement

Log in

Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer

International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2017 for the Treatment of Uterine Cervical Cancer are for the purpose of providing standard treatment strategies for cervical cancer, indicating treatment methods currently considered appropriate for cervical cancer, minimizing variances in treatment methods among institutions, improving the safety of treatment and prognosis of diseases, reducing the economic and psychosomatic burden of patients by promoting performance of appropriate treatment, and enhancing mutual understanding between patients and healthcare professionals. The guidelines were prepared through consensus of the JSGO Guideline Committee, based on careful review of evidence gathered through the literature searches and in view of the medical health insurance system and actual clinical practice situations in Japan. The guidelines comprise eight chapters and five algorithms. The main features of the 2017 revision are as follows: (1) evidence was collected using a search formula and with cooperation of the Japan Library Association. The bibliographical search formula was placed at the end of the book; (2) regarding clinical questions (CQs) where evidence or clinical inspection in Japan was lacking, opinions of the Guidelines Committee were described as “proposals for future directions”; (3) cervical intraepithelial neoplasia (CIN) 3 and adenocarcinoma in situ (AIS) were treated as a cervical precancerous lesion; (4) the CQs of endoscopic surgery, radical trachelectomy, and sentinel node biopsy were newly added in Chapter 3, “primary treatment for stage IB–II cervical cancer”; and (5) the CQ about hormone replacement therapy after cancer treatment was newly established. Each recommendation is accompanied by a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSGO Guidelines 2017 for the Treatment of Uterine Cervical Cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Abbreviations

AIS:

Adenocarcinoma in situ

CCRT:

Concurrent chemoradiotherapy

CIN:

Cervical intraepithelial neoplasia

COIs:

Conflicts of interests

CQs:

Clinical questions

CTV:

Clinical target volume

EORTC:

European Organization for Research and Treatment of Cancer

FIGO:

International Federation of Gynecology and Obstetrics

Gy:

Gray

HPV:

Human papillomavirus

HRT:

Hormone replacement therapy

HSIL:

High-grade squamous intraepithelial lesion

IMRT:

Intensity-modulated radiation therapy

JCOG:

Japan Clinical Oncology Group

JGOG:

Japanese Gynecologic Oncology Group

JSCO:

Japan Society of Clinical Oncology

JSGO:

Japan Society of Gynecologic Oncology

LSIL:

Low-grade squamous intraepithelial lesion

Minds:

Medical Information Network Distribution Service

NAC:

Neoadjuvant chemotherapy

NCCN:

National Comprehensive Cancer Network

PTV:

Planning target volume

QOL:

Quality of life

RCT:

Randomized controlled trial

RTOG:

Radiation Therapy Oncology Group

SIL:

Squamous intraepithelial lesion

TC:

Paclitaxel plus carboplatin

TP:

Paclitaxel plus cisplatin

WBRT:

Whole-brain radiation therapy

WHO:

World Health Organization

3D-CRT:

3 dimensional-conformal radiotherapy

References

  1. National Cancer Center, Japan (2016) Cancer registry and statistics. Ministry of Health, Labour and Welfare, Tokyo

    Google Scholar 

  2. Nagase S, Inoue Y, Umesaki N et al (2010) Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. Int J Clin Oncol 15:117–124

    Article  PubMed  Google Scholar 

  3. Ebina Y, Yaegashi N, Katabuchi H et al (2015) Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer. Int J Clin Oncol 20:240–248

    Article  PubMed  Google Scholar 

  4. Ariyoshi H (2002) Guideline for correct use of antineoplastic agents (draft). General theory. Gan To Kagaku Ryoho 29:970–977

    PubMed  Google Scholar 

  5. Ochiai K, Okamoto A, Katsumata N (2002) Guidelines for proper use of antineoplastic agents. Gynecologic cancer. Gan To Kagaku Ryoho 29:1047–1054

    PubMed  Google Scholar 

  6. Fukui T, Yoshida M, Yamaguchi N et al (2007) Minds handbook on preparation of treatment guidelines 2007. Igaku Shoin, Tokyo

    Google Scholar 

  7. Yamaguchi N, Morizane T, Kojimahara N et al (2014) Minds handbook on preparation of treatment guidelines 2014. Igaku Shoin, Tokyo

    Google Scholar 

  8. Stoler M, Bergeron C, Colgan TJ et al (2014) Squmous cell tumours and precursors. In: Kurman RJ, Carcangiu ML, Herrington CS et al (ed) World Health Organization classification of tumours, 4th edn. Tumours of Female Reproductive Organs. Lyon, IARC Press, Lyon, pp 172–182

    Google Scholar 

  9. Japanese Society of Obstetrics and Gynecology, Japan Society of Pathology (2017) The general rules for clinicaland pathological management of uterine cervical cancer, pathological edition, 4th edn. Kanehara-shuppan, Tokyo

    Google Scholar 

  10. van Meurs H, Visser O, Buist MR et al (2009) Frequency of pelvic lymph node metastases and parametrial involvement in stage IA2 cervical cancer: a population-based study and literature review. Int J Gynecol Cancer 19:21–26

    Article  PubMed  Google Scholar 

  11. Katabuchi H (2016) Gynecologic cancer comittee report in 2014. Acta Obstet Gynaecol Jpn 68:1117–1160

    Google Scholar 

  12. Cervical Cancer Guideline (Version 1) (2016) NCCN clinical practice guidelines in oncology

  13. Long Y, Yao DS, Pan XW et al (2014) Clinical efficacy and safety of nerve-sparing radical hysterectomy for cervical cancer: a systematic review and meta-analysis. PLoS One 9:e94116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Roh JW, Lee DO, Suh DH et al (2015) Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial. J Gynecol Oncol 26:90–99

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ramirez PT, Jhingran A, Macapinlac HA et al (2011) Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer 117:1928–1934

    Article  PubMed  Google Scholar 

  16. Cosin JA, Fowler JM, Chen MD et al (1998) Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. Cancer 82:2241–2248

    Article  CAS  PubMed  Google Scholar 

  17. Brockbank E, Kokka F, Bryant A et al (2013) Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer. Cochrane Database Syst Rev 2013:CD008217

    Google Scholar 

  18. Sevin BU, Nadji M, Lampe B et al (1995) Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer 76:1978–1986

    Article  CAS  PubMed  Google Scholar 

  19. Lin HH, Cheng WF, Chan KW et al (1996) Risk factors for recurrence in patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation. Obstet Gynecol 88:274–279

    Article  CAS  PubMed  Google Scholar 

  20. Roman LD, Felix JC, Muderspach LI et al (1998) Influence of quantity of lymph-vascular space invasion on the risk of nodal metastases in women with early-stage squamous cancer of the cervix. Gynecol Oncol 68:220–225

    Article  CAS  PubMed  Google Scholar 

  21. Comerci G, Bolger BS, Flannelly G et al (1998) Prognostic factors in surgically treated stage IB-IIB carcinoma of the cervix with negative lymph nodes. Int J Gynecol Cancer 8:23–26

    Article  PubMed  Google Scholar 

  22. Kim SM, Choi HS, Byun JS (2000) Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. Int J Gynecol Cancer 10:305–312

    Article  PubMed  Google Scholar 

  23. Trattner M, Graf AH, Lax S et al (2001) Prognostic factors in surgically treated stage Ib-IIb cervical carcinomas with special emphasis on the importance of tumor volume. Gynecol Oncol 82:11–16

    Article  CAS  PubMed  Google Scholar 

  24. Takeda N, Sakuragi N, Takeda M et al (2002) Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand 81:1144–1151

    Article  PubMed  Google Scholar 

  25. Morice P, Piovesan P, Rey A et al (2003) Prognostic value of lymphovascular space invasion determined with hematoxylin-eosin staining in early stage cervical carcinoma: results of a multivariate analysis. Ann Oncol 14:1511–1517

    Article  CAS  PubMed  Google Scholar 

  26. Rutledge TL, Kamelle SA, Tillmanns TD et al (2004) A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol 95:70–76

    Article  PubMed  Google Scholar 

  27. Chen SW, Liang JA, Yang SN et al (2004) Early stage cervical cancer with negative pelvic lymph nodes: pattern of failure and complication following radical hysterectomy and adjuvant radiotherapy. Eur J Gynaecol Oncol 25:81–86

    PubMed  Google Scholar 

  28. Delgado G, Bundy B, Zaino R et al (1990) Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 38:352–357

    Article  CAS  Google Scholar 

  29. Lai CH, Hong JH, Hsueh S et al (1999) Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases. Cancer 85:1537–1546

    Article  CAS  PubMed  Google Scholar 

  30. Japanese Society of Obstetrics and Gynecology, Japan Society of Pathology (2012) The general rules for clinical and pathological management of uterine cervical cancer, 3rd edn. Kanehara-shuppan, Tokyo

    Google Scholar 

  31. Japanese Society for Radiation Oncology (2012) Guidelines of radiotherapy treatment planning 2012. Kanehara-shuppan, Tokyo

    Google Scholar 

  32. Small W Jr., Mell LK, Anderson P et al (2008) Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 71:428–434

    Article  PubMed  Google Scholar 

  33. Japan Clinical Oncology Group, Toita T, Ohno T et al (2010) A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol 40: 456–463

    Article  Google Scholar 

  34. Perez CA, Kavanagh BD (2008) Uterine cervix. In: Perez CA, Brady LW (eds) Principles and practice of radiation oncology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1800–1915

    Google Scholar 

  35. Mundt AJ, Mell LK, Roeske JC (2003) Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 56:1354–1360

    Article  PubMed  Google Scholar 

  36. Jhingran A (2006) Potential advantages of intensity-modulated radiation therapy in gynecologic malignancies. Semin Radiat Oncol 16:144–151

    Article  PubMed  Google Scholar 

  37. Chen MF, Tseng CJ, Tseng CC et al (2007) Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 67:1438–1444

    Article  CAS  PubMed  Google Scholar 

  38. Klopp AH, Moughan J, Portelance L et al (2016) Pilot study of a computed tomography-compatible shielded intracavitary brachytherapy applicator for treatment of cervical cancer. Pract Radiat Oncol 3:115–123

    Article  Google Scholar 

  39. Murakami N, Okamoto H, Kasamatsu T et al (2014) A dosimetric analysis of intensity-modulated radiation therapy with bone marrow sparing for cervical cancer. Anticancer Res 34:5091–5098

    PubMed  Google Scholar 

  40. Rotman M, Pajak TF, Choi K et al (1995) Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79 – 20. JAMA 274:387–393

    Article  CAS  PubMed  Google Scholar 

  41. Haie C, Pejovic MH, Gerbaulet A et al (1988) Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiother Oncol 11:101–112

    Article  CAS  PubMed  Google Scholar 

  42. Toita T, Kitagawa R, Hamano T et al (2012) Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Gynecol Oncol 126:211–216

    Article  CAS  PubMed  Google Scholar 

  43. Kato S, Ohno T, Thephamongkhol K et al (2010) Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia. Int J Radiat Oncol Biol Phys 77:751–757

    Article  PubMed  Google Scholar 

  44. Toita T, Moromizato H, Ogawa K et al (2005) Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer. Gynecol Oncol 96:665–670

    Article  PubMed  Google Scholar 

  45. Sakata K, Sakurai H, Suzuki et al (2008) Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: study of JROSG (Japan Radiation Oncology Study Group). Acta Oncol 47:434–441

    Article  CAS  PubMed  Google Scholar 

  46. Monk BJ, Sill MW, McMeekin DS et al (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27:4649–4655

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Moore KN, Herzog TJ, Lewin S et al (2007) A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 105:299–303

    Article  CAS  PubMed  Google Scholar 

  48. Kitagawa R, Katsumata N, Shibata T et al (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 33:2129–2135

    Article  CAS  PubMed  Google Scholar 

  49. Grigsby PW (2005) Radiotherapy for pelvic recurrence after radical hysterectomy for cervical cancer. Radiat Med 23:327–330

    PubMed  Google Scholar 

  50. Thomas GM, Dembo AJ, Myhr T et al (1993) Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. Int J Gynecol Cancer 3:193–198

    Article  PubMed  Google Scholar 

  51. Ito H, Shigematsu N, Kawada T et al (1997) Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy. Gynecol Oncol 67:154–161

    Article  CAS  PubMed  Google Scholar 

  52. Noda K, Ikeda M, Yakushiji M et al (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus]. Gan To Kagaku Ryoho 19:885–892

    CAS  PubMed  Google Scholar 

  53. Kato T, Nishimura H, Yakushiji M et al (1992) Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer. Gan To Kagaku Ryoho 19:695–701

    CAS  PubMed  Google Scholar 

  54. Tsuda H, Hashiguchi Y, Nishimura S et al (2004) Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer 91:1032–1037

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Takekuma M, Hirashima Y, Ito K et al (2012) Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study. Gynecol Oncol 126:341–345

    Article  CAS  PubMed  Google Scholar 

  56. Donegan WL (1983) Cancer and pregnancy. CA Cancer J Clin 33:194–214

    Article  CAS  PubMed  Google Scholar 

  57. Abe Y, Ito K, Okamura C et al (2004) Cervical cytologic examination during physical checkup of pregnant women: cervical cancer screening in women under the age of thirty. Tohoku J Exp Med 204:221–228

    Article  PubMed  Google Scholar 

  58. Zemlickis D, Lishner M, Degendorfer P et al (1991) Maternal and fetal outcome after invasive cervical cancer in pregnancy. J Clin Oncol 9:1956–1961

    Article  CAS  PubMed  Google Scholar 

  59. Morice P, Uzan C, Gouy S et al (2012) Gynaecological cancers in pregnancy. Lancet 379:558–569

    Article  PubMed  Google Scholar 

  60. Lanceley A, Fiander A, McCormack et al (2013) Followup protocols for women with cervical cancer after primary treatment. Cochrane Database Syst Rev 2013:CD008767

    Google Scholar 

  61. Elit L, Fyles AW, Devries MC et al (2009) Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 114:528–535

    Article  PubMed  Google Scholar 

  62. Salani R, Backes FJ, Fung MF et al (2011) Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 204:466–478

    Article  PubMed  Google Scholar 

  63. Matsuura Y, Kawagoe T, Toki N et al (2006) Long-standing complications after treatment for cancer of the uterine cervix–clinical significance of medical examination at 5 years after treatment. Int J Gynecol Cancer 16:294–297

    Article  CAS  PubMed  Google Scholar 

  64. Greimel ER, Winter R, Kapp KS et al (2009) Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology 18:476–482

    Article  PubMed  Google Scholar 

  65. Park SY, Bae DS, Nam JH et al (2007) Quality of life and sexual problems in disease-free survivors of cervical cancer compared with the general population. Cancer 110:2716–2725

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Japanese Society of Obstetrics and Gynecology (JSOG), the Japan Society of Clinical Oncology (JSCO), the Japan Society of Gynecologic and Obstetric Endoscopy and Minimally Invasive Therapy, the Japanese Gynecologic Oncology Group (JGOG), the Japan Association of Obstetricians and Gynecologists (JAOG), the Japan Society of Pathology (JSP), the Japanese Society for Radiation Oncology (JASTRO) for their comments and contributions throughout the project. We also acknowledge the clerical and technical assistance by Ms Toshie Yasuda of JSGO and Ms Yuriko Adachi of Kanehara CO., LTD.

Members of Guidelines Committee (alphabetical order)

Masanori Kaneuchi, Hidetaka Katabuchi, Mikio Mikami, Satoru Nagase, Tsutomu Tabata. Yasuhiro Udagawa, Nobuo Yaegashi.

Members of guidelines drafting committee (alphabetical order)

Tsukasa Baba, Yasuhiko Ebina, Takayuki Enomoto, Kazuhiko Hayashi, Yasuyuki Hirashima, Takashi Iwata, Shingo Kato, Noriyuki Katsumata, Atsumi Kojima, Tetsuji Kurokawa, Masaki Mandai, Yoshiki Mikami, Toshinari Muramatsu, Yutaka Nagai, Hidekatsu Nakai, Kentaro Nakayama, Hitoshi Niikura, Katsutoshi Oda, Hideyuki Ohtake, Masayuki Sekine, Muneaki Shimada, Tsutomu Tabata, Kiyomi Takaishi, Kiyoshi Takamatsu, Kazuhiro Takehara, Hironori Tashiro, Takafumi Toita, Satoshi Yamaguchi, Masanori Yasuda, Kiyoshi Yoshino.

Members of guidelines evaluation committee (alphabetical order)

Daisuke Aoki, Yoichi Aoki, Takuma Fujii, Keiichi Fujiwara, Toru Hachisuga, Toshio Hamatani, Kenichi Hrano, Kazuhiko Ino, Atsuko Itakura, Kiyoshi Ito, Osamu Iwanari, Seiryu Kamoi, Takahiro Kasamatsu, Naoki Kawamura, Hiroaki Kobayashi, Hiroshi Kobayashi, Takeshi Kodaira, Kaneyuki Kubushiro, Etsuko Miyagi, Mika Mizuno, Kenichiro Morishige, Tetsuro Nagasaka, Toshiaki Nakamura, Masahide Ohmichi, Aikou Okamoto, Takashi Onda, Tsuyoshi Saito, Toshiaki Saito, Noriaki Sakuragi, Toyomi Sato, Tadashi Shiraishi, Toru Sugiyama, Nao Suzuki, Mitsuaki Suzuki, Masashi Takano, Nobuhiro Takeshima, Takashi Uno, Kimio Ushijima, Yoh Watanabe, Hiroko Yokota, Hiroyuki Yoshikawa.

Patient advocacy group “Katorea no Mori”.

Funding

Preparation of these guidelines was funded by the JSGO. No financial support was received from any other organization or corporation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yasuhiko Ebina.

Ethics declarations

Conflict of interest

(1) The Conflicts of Interest Committee of the JSGO discloses information on real or potential COIs of the members of the Drafting and Evaluation Committees for the Guidelines, as well as other relevant parties. The information can be confirmed via the Policy on Conflicts of Interest among Clinical Cancer Researchers, which can be viewed at http://www.jsgo.or.jp/topics/index01.html (prepared by JSGO; in Japanese). The following corporations were disclosed by self‑declaration of the Drafting Committee members. ASKA Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; TSUMURA & Co.; Zeria Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Bayer Yakuhin Ltd.; Pfizer Japan Inc.; and Roche Diagnostics Co., Ltd. (2) Each recommendation was determined through consensus of all committee members and was not influenced by the interests of specific organizations, products, or technologies.

Additional information

This article originally appeared in Japanese as Shikyu keigan chiryo gaidorain 2017 nen ban, published by Kanehara, Tokyo, 2017.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ebina, Y., Mikami, M., Nagase, S. et al. Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. Int J Clin Oncol 24, 1–19 (2019). https://doi.org/10.1007/s10147-018-1351-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-018-1351-y

Keywords

Navigation